PU film balloon approved by FDA for obesity treatment

The US Food and Drug Administration has granted premarket approval to the Allurion Gastric Balloon System, a swallowable, non-surgical weight-loss device designed to provide an alternative to pharmacological therapies such as GLP-1 receptor agonist drugs and bariatric surgery. The system, developed by Boston-area medical technology company Allurion Technologies, is indicated for adults with a body-mass index of 30–40 kg/m² who have not succeeded with structured weight-loss attempts.

Unlike traditional intragastric balloons that require endoscopy or anaesthesia, the Allurion device is ingested as a capsule during a 15-minute office visit, then filled with fluid once it reaches the stomach, where it occupies volume to promote early satiety and lower caloric intake. After approximately four months, a patented release valve automatically opens, allowing the balloon to deflate and pass naturally through the gastrointestinal tract without a secondary retrieval procedure. A subsequent balloon can be administered about two months after the first passes if additional treatment cycles are desired.

The FDA’s approval comes amid growing demand for non-pharmacologic and finite interventions that do not require chronic weekly or daily medication regimens, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide and tirzepatide, which remain the dominant class of weight-loss pharmaceuticals. Real-world data from more than 200,000 international patients who have used the Allurion balloon indicate meaningful weight reduction outcomes and a safety profile that is generally favourable relative to longer-term, traditional gastric balloon systems.

The approval expands the obesity-care toolkit in the United States, offering clinicians a procedure-less, finite treatment option that sits alongside emerging oral and injectable therapies. This aligns with broader trends in obesity management, where patient preferences and tolerability influence adoption of devices, medications and combination approaches.

Photo: An Allurion balloon after (left) and before (right) inflation (© Allurion).

Allurion